

**PART 530—EXTRALABEL DRUG USE IN ANIMALS**

■ 1. The authority citation for 21 CFR part 530 continues to read as follows:

**Authority:** 15 U.S.C. 1453, 1454, 1455; 21 U.S.C. 321, 331, 351, 352, 353, 355, 357, 360b, 371, 379e.

■ 2. In § 530.41, add paragraph (a)(13) to read as follows:

**§ 530.41 Drugs prohibited for extralabel use in animals.**

(a) \* \* \*

(13) Cephalosporins (not including cephalirin) in cattle, swine, chickens, or turkeys:

(i) For disease prevention purposes;  
(ii) At unapproved doses, frequencies, durations, or routes of administration;  
or

(iii) If the drug is not approved for that species and production class.

\* \* \* \* \*

Dated: November 23, 2011.

**Bernadette Dunham,**

*Director, Center for Veterinary Medicine.*

[FR Doc. 2012-35 Filed 1-4-12; 11:15 am]

**BILLING CODE 4160-01-P**

**DEPARTMENT OF DEFENSE****Office of the Secretary**

[DOD-2010-OS-0043; RIN 0790-A162]

**32 CFR Part 222****DoD Mandatory Declassification Review (MDR) Program; Correction**

**AGENCY:** Department of Defense.

**ACTION:** Final rule; correction.

**SUMMARY:** On December 27, 2011 (76 FR 80744-80747), Department of Defense published a final rule titled DoD Mandatory Declassification Review (MDR) Program, which assigns responsibilities and provides procedures for members of the public to request a declassification review of information classified under the provisions of Executive Order 13526, or predecessor orders. This rule corrects a paragraph identification error in the regulations.

**DATES:** This correction is effective January 26, 2012.

**FOR FURTHER INFORMATION CONTACT:** Patricia Toppings, (571) 372-0485.

**SUPPLEMENTARY INFORMATION:** On December 27, 2011, Department of Defense published a final rule titled DoD Mandatory Declassification Review (MDR) Program. Subsequent to the publication of that final rule,

Department of Defense discovered that paragraph § 222.5(f) in the third column of page 80746 should have read § 222.5(j).

**Correction**

In the final rule (FR Doc. 2011-33104) published on December 27, 2011 (76 FR 80744-80747), make the following correction:

**§ 222.5 [Corrected]**

On page 80746, in § 222.5, in the third column, in the first line of the third paragraph, “(f) *MDR Appeals*.” should read “(j) *MDR Appeals*.”

Dated: December 30, 2011.

**Aaron Siegel,**

*Alternate OSD Federal Register Liaison Officer, Department of Defense.*

[FR Doc. 2011-33857 Filed 1-5-12; 8:45 am]

**BILLING CODE 5001-06-P**

**ENVIRONMENTAL PROTECTION AGENCY****40 CFR Part 52**

[EPA-R09-OAR-2011-0547; FRL-9480-1]

**Revisions to the California State Implementation Plan, San Joaquin Valley Unified Air Pollution Control District (SJVUAPCD)****Correction**

In rule document 2011-33660 appearing on pages 214-217 in the issue of Wednesday, January 4, 2012, make the following corrections:

(1) On page 214, in the second column, in the DATES section, in the second line, “February 3, 2011” should read “February 3, 2012”.

(2) On page 217, in the first column, in the last paragraph, in the fifth line, “March 7, 2011” should read “March 5, 2012”.

[FR Doc. C1-2011-33660 Filed 1-5-12; 8:45 am]

**BILLING CODE 1505-01-D**

**ENVIRONMENTAL PROTECTION AGENCY****40 CFR Part 180**

[EPA-HQ-OPP-2010-0944; FRL-9330-4]

**Bacillus Amyloliquefaciens Strain D747; Exemption From the Requirement of a Tolerance**

**AGENCY:** Environmental Protection Agency (EPA).

**ACTION:** Final rule.

**SUMMARY:** This regulation establishes an exemption from the requirement of a

tolerance for residues of the *Bacillus amyloliquefaciens* strain D747 (formerly known as *Bacillus subtilis* variant *amyloliquefaciens* strain D747) in or on all food commodities when used in accordance with good agricultural practices. Certis USA LLC submitted a petition to EPA under the Federal Food, Drug, and Cosmetic Act (FFDCA), requesting an exemption from the requirement of a tolerance. This regulation eliminates the need to establish a maximum permissible level for residues of *Bacillus amyloliquefaciens* strain D747 (formerly known as *Bacillus subtilis* variant *amyloliquefaciens* strain D747).

**DATES:** This regulation is effective January 6, 2012. Objections and requests for hearings must be received on or before March 6, 2012, and must be filed in accordance with the instructions provided in 40 CFR part 178 (see also Unit I.C. of the **SUPPLEMENTARY INFORMATION**).

**ADDRESSES:** EPA has established a docket for this action under docket identification (ID) number EPA-HQ-OPP-2010-0944. All documents in the docket are listed in the docket index available at <http://www.regulations.gov>. Although listed in the index, some information is not publicly available, e.g., Confidential Business Information (CBI) or other information the disclosure of which is restricted by statute. Certain other material, such as copyrighted material, is not made available via the Internet and will be publicly available only in hard copy form. Publicly available docket materials are available in the electronic docket at <http://www.regulations.gov>, or, if only available in hard copy, at the OPP Regulatory Public Docket in Rm. S-4400, One Potomac Yard (South Bldg.), 2777 S. Crystal Dr., Arlington, VA. The Docket Facility is open from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The Docket Facility telephone number is (703) 305-5805.

**FOR FURTHER INFORMATION CONTACT:** Susanne Cerrelli, Biopesticides and Pollution Prevention Division (7511P), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave. NW., Washington, DC 20460-0001; telephone number: (703) 308-8077; email address: [cerrelli.susanne@epa.gov](mailto:cerrelli.susanne@epa.gov).

**SUPPLEMENTARY INFORMATION:****I. General Information****A. Does this action apply to me?**

You may be potentially affected by this action if you are an agricultural